文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于基因表达综合数据库（GEO）的卵巢癌中 MicroRNA-9 的前瞻性通路信号和预后价值：一项生物信息学分析。

Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.

机构信息

Department of Oncology, Fudan University Shanghai Cancer Center, Minhang Branch, 106 Ruili road, Minhang district, Shanghai, 200240, China.

出版信息

J Ovarian Res. 2021 Feb 9;14(1):29. doi: 10.1186/s13048-021-00779-z.

DOI:10.1186/s13048-021-00779-z
PMID:33563317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7874475/
Abstract

OBJECTIVE: MicroRNAs (miRNAs) play a vital role in the development of ovarian cancer (OC). The aim of this study to investigate the prognostic value and potential signaling pathways of hsa-miR-9-5p (miR-9) in OC through literature review and bioinformatics methods. METHODS: The expression of miR-9 in OC was assessed using the public datasets from the Gene Expression Omnibus (GEO) database. And a literature review was also performed to investigate the correlation between miR-9 expression and the OC prognosis. Two mRNA datasets (GSE18520 and GSE36668) of OC tissues and normal ovarian tissues (NOTs) were downloaded from GEO to identify the differentially expressed genes (DEGs). The target genes of hsa-miR-9-5p (TG-miR-9-5p) were predicted using miRWALK3.0 and TargetScan. Then the gene overlaps between DEGs in OC and the predicted TG-miR-9-5p were confirmed using a Venn diagram. After that, overlapping genes were subjected to Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Finally, a protein-protein interaction (PPI) network was constructed using STRING and Cytoscape, and the impact of hub genes on OC prognosis was analyzed. RESULTS: It was found that OC patients with miR-9 low expression had poor prognosis. A total of 107 DEGs related to both OC and miR-9 were identified. Dozens of DEGs were enriched in developmental process, extracellular matrix structural constituent, cell junction, axon guidance. In the PPI network analysis, 5 of the top 10 hub genes was significantly associated with decreased overall survival of OC patients, namely FBN1 (HR = 1.64, P < 0.05), PRRX1 (HR = 1.76, P < 0.05), SMC2 (HR = 1.22, P < 0.05), SMC4 (HR = 1.31, P < 0.05), and VCAN (HR = 1.48, P < 0.05). CONCLUSION: Low expression of miR-9 indicates poor prognosis of OC patients. MiR-9 plays a crucial role in the biological process of OC by binding to target genes, thus affecting the prognosis of patients.

摘要

目的：微小 RNA（miRNA）在卵巢癌（OC）的发展中起着至关重要的作用。本研究通过文献回顾和生物信息学方法，探讨 hsa-miR-9-5p（miR-9）在 OC 中的预后价值和潜在信号通路。

方法：使用基因表达综合数据库（GEO）公共数据集评估 miR-9 在 OC 中的表达。并进行文献复习，探讨 miR-9 表达与 OC 预后的相关性。从 GEO 下载两个 OC 组织和正常卵巢组织（NOT）的 mRNA 数据集（GSE18520 和 GSE36668），以鉴定差异表达基因（DEGs）。使用 miRWALK3.0 和 TargetScan 预测 hsa-miR-9-5p 的靶基因（TG-miR-9-5p）。然后使用 Venn 图确认 OC 中的 DEGs 与预测的 TG-miR-9-5p 之间的基因重叠。之后，对重叠基因进行基因本体论（GO）富集分析和京都基因与基因组百科全书（KEGG）通路分析。最后，使用 STRING 和 Cytoscape 构建蛋白质-蛋白质相互作用（PPI）网络，并分析关键基因对 OC 预后的影响。

结果：发现 miR-9 低表达的 OC 患者预后不良。共鉴定出 107 个与 OC 和 miR-9 相关的 DEGs。数十个 DEGs 富集在发育过程、细胞外基质结构成分、细胞连接、轴突导向等过程中。在 PPI 网络分析中，前 10 个 hub 基因中有 5 个与 OC 患者总生存率降低显著相关，即 FBN1（HR=1.64，P<0.05）、PRRX1（HR=1.76，P<0.05）、SMC2（HR=1.22，P<0.05）、SMC4（HR=1.31，P<0.05）和 VCAN（HR=1.48，P<0.05）。

结论：miR-9 的低表达预示着 OC 患者预后不良。miR-9 通过与靶基因结合在 OC 的生物学过程中发挥关键作用，从而影响患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/9ef3b333ae5c/13048_2021_779_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/f2dc0fab2cbe/13048_2021_779_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/42bf5ea491e1/13048_2021_779_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/6f6c742a4f23/13048_2021_779_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/bbdeff7ac310/13048_2021_779_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/57be1ef4a266/13048_2021_779_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/8249a180c5d7/13048_2021_779_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/1e919812996f/13048_2021_779_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/6705b5c108ee/13048_2021_779_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/ce16c155c01e/13048_2021_779_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/9ef3b333ae5c/13048_2021_779_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/f2dc0fab2cbe/13048_2021_779_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/42bf5ea491e1/13048_2021_779_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/6f6c742a4f23/13048_2021_779_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/bbdeff7ac310/13048_2021_779_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/57be1ef4a266/13048_2021_779_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/8249a180c5d7/13048_2021_779_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/1e919812996f/13048_2021_779_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/6705b5c108ee/13048_2021_779_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/ce16c155c01e/13048_2021_779_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbde/7874475/9ef3b333ae5c/13048_2021_779_Fig10_HTML.jpg

相似文献

[1]
Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.

J Ovarian Res. 2021-2-9

[2]
Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.

J Ovarian Res. 2019-11-8

[3]
Bioinformatics analysis of prognostic value and prospective pathway signal of miR-30a in ovarian cancer.

J Ovarian Res. 2020-10-1

[4]
Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.

J Ovarian Res. 2020-1-27

[5]
Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.

BMC Cancer. 2021-4-23

[6]
Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.

PLoS One. 2021

[7]
Construction of novel mRNA-miRNA-lncRNA regulatory networks associated with prognosis of ovarian cancer.

J Cancer. 2020-10-17

[8]
Bioinformatics Analysis Identifies the Estrogen Receptor 1 (ESR1) Gene and hsa-miR-26a-5p as Potential Prognostic Biomarkers in Patients with Intrahepatic Cholangiocarcinoma.

Med Sci Monit. 2020-5-21

[9]
Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis.

J Ovarian Res. 2019-4-22

[10]
Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments.

J Cell Physiol. 2019-1-11

引用本文的文献

[1]
Novel De Novo Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway.

Int J Mol Sci. 2025-3-5

[2]
LncRNA KIFAP3-5:1 inhibits epithelial-mesenchymal transition of renal tubular cell through PRRX1 in diabetic nephropathy.

Cell Biol Toxicol. 2024-6-13

[3]
The extracellular matrix glycoprotein fibrillin-1 in health and disease.

Front Cell Dev Biol. 2024-1-10

[4]
miR-9-5p expression is associated with vascular invasion and prognosis in hepatocellular carcinoma, and in vitro verification.

J Cancer Res Clin Oncol. 2023-11

本文引用的文献

[1]
MiR-9-5p Inhibits the Proliferation, Migration and Invasion of Choroidal Melanoma by Targeting BRAF.

Technol Cancer Res Treat. 2020

[2]
LncRNA LINC01116 Promotes the Development of Colorectal Cancer by Targeting miR-9-5p/STMN1.

Onco Targets Ther. 2020-10-15

[3]
Prognostic gene expression signature for high-grade serous ovarian cancer.

Ann Oncol. 2020-9

[4]
Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer.

BMC Cancer. 2019-12-30

[5]
MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies.

Cells. 2019-12-20

[6]
CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer.

Mol Cancer. 2019-10-17

[7]
Modulation of microRNAs by aspirin in cardiovascular disease.

Trends Cardiovasc Med. 2019-8-14

[8]
MiR-9 accelerates epithelial-mesenchymal transition of ovarian cancer cells via inhibiting e-cadherin.

Eur Rev Med Pharmacol Sci. 2019-8

[9]
Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.

Cell Cycle. 2019-7-1

[10]
MicroRNA-34a suppresses human lens epithelial cell proliferation and migration via downregulation of c-Met.

Clin Chim Acta. 2019-4-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索